STOCKHOLM, April 20, 2026 /PRNewswire/ — Securitas AB will publish the Interim Report January-March 2026 on Tuesday April 28, 2026, at 8.00 a.m. (CEST).

8.00 a.m. (CEST) Report release
The report will be sent as a press release from Cision (www.cision.se) and will automatically be published on www.securitas.com when released.

9.00 a.m. (CEST) Presentation slides available
For presentation slides, follow the link
www.securitas.com/en/investors/financial-reports-and-presentations

9.30 a.m. (CEST) Telephone conference and audio cast
Analysts and media are invited to participate in a telephone conference at 9.30 a.m. where Securitas President and CEO Magnus Ahlqvist and CFO Matteo Dall’Ora will present the report and answer questions. The telephone conference will also be audio casted live via Securitas’ website.

To follow the audio cast of the telephone conference via the web, please follow the link www.securitas.com/en/investors/financial-reports-and-presentations

Questions for the management can be placed by phone. To ask questions by phone, access to the teleconference register by clicking on the link To the teleconference.

If you wish to ask a question, please dial *5 on your telephone keypad to enter the queue.  

A recorded version of the audio cast will be available on the same web page after the telephone conference. We value your privacy and want to be transparent with you on the way that we collect and use your personal data when you participate in the telephone conference. Please follow this link to read our privacy policy for telephone conferences/audio casts in relation to publication of interim reports: www.securitas.com/privacy-policy-audiocasts.

Further information: 

Investors: Carina Florén, IR Manager; +46 73 719 21 01, carina.floren@securitas.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/securitas/r/securitas-ab-to-publish-the-interim-report-january-march-2026-on-april-28–2026,c4336868

The following files are available for download:

View original content:https://www.prnewswire.co.uk/news-releases/securitas-ab-to-publish-the-interim-report-january-march-2026-on-april-28-2026-302747152.html

Company intends to monetize its foundational patent portfolio in the global $150 billion battery market

DALLAS, April 20, 2026 /CNW/ — Solidion Technology Inc. (“Solidion” or the “Company”) (Nasdaq: STI), an advanced battery technology solutions provider, announced that it has entered into a binding agreement with the IP Services Practice of Hilco Global (a subsidiary of Orix Company) to monetize its foundational energy portfolio and enforce its patent rights. Hilco has analyzed the Solidion patent portfolio to identify high value assets and the patent data suggest that a significant number of global companies will likely require a license to the Solidion portfolio.  In the energy storage segment in particular, virtually all the major players in the industry have technology that overlaps with the Solidion portfolio and the same appears to be true in semiconductors, consumer electronics and aerospace.

Jaymes Winters, Chief Executive Officer of Solidion Technology, stated:

“The entire energy storage ecosystem has repetitiously utilized several of Solidion’s foundational patents to monetize their business models at a level rarely seen before. These are not just mom and pop startups, most of them are worldly known household names and industry leaders in not just EV battery storage, but other sectors such as semiconductors, aircraft and automotive manufacturing and cutting edge materials. The value of Solidion’s portfolio could exceed $750 million.”

Karl Maersch, head of the Patent Analysis & Monetization Group at Hilco IP Services, stated:

“Solidion’s portfolio covers various aspects of graphene and battery technology and it has applicability across multiple industry segments and includes companies that compete with Solidion and companies in adjacent technology segments.  In our view, the portfolio shows significant indicia of value and we are excited to partner with Solidion to help the company extract revenue from its portfolio.”

About Solidion Technology, Inc.

Headquartered in Dallas, Texas with pilot production facilities in Dayton, Ohio, Solidion’s (NASDAQ: STI) core business includes manufacturing of  battery materials and components, as well as development and production of next-generation batteries for energy storage systems, including including UPS systems serving the artificial intelligence (AI) data center market and electric vehicles for ground, aerospace, and sea transportation. Solidion holds a portfolio of over 345 patents, covering innovations such as high-capacity, silane gas free and graphene-enabled silicon anodes, biomass-based graphite, advanced lithium-sulfur and lithium-metal technologies.

For more information, please visit www.solidiontech.com or contact Investor Relations.

About Hilco Global

Hilco Global, a subsidiary of ORIX Corporation USA, is a diversified financial services company that delivers integrated professional services and capital solutions that help clients maximize value and drive performance across the retail, commercial and industrial, real estate, manufacturing, brand and intellectual property sectors, and more. Hilco Global provides a range of customized solutions to healthy, stressed, and distressed companies to resolve complex situations and enhance long-term enterprise value. Hilco Global works to deliver the best possible result by aligning interests with clients and providing strategic advice and, in many instances, the capital required to complete the deal. Hilco Global is based in Northbrook, Illinois and has more than 810 professionals operating on four continents.

Visit www.hilcoglobal.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Solidion Technology Inc., (NASDAQ: STI) (the “Company,” “Solidion,” “we,” “our” or “us”) desires to take advantage of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and is including this cautionary statement in connection with this safe harbor legislation. The words “forecasts” “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise, except as may be required by law.

View original content to download multimedia:https://www.prnewswire.com/news-releases/solidion-technology-enters-into-binding-strategic-patent-monetization-agreement-with-hilco-global-302746839.html

SOURCE Solidion Technology, Inc.

WASHINGTON, April 20, 2026 /PRNewswire/ — Floreo, a developer of virtual reality (VR)-based therapeutic technologies, today announced the submission of a De Novo request to the U.S. Food and Drug Administration (FDA) for FloreoRx, its software-based product being evaluated for use in supporting skill development in individuals with Autism Spectrum Disorder. FloreoRx is an investigational device and has not yet been cleared or approved by the FDA.

In 2023, Floreo became the first VR autism technology to receive the FDA’s Breakthrough Device Designation, a program designed to expedite the development and review of technologies that may provide more effective treatment for serious conditions.

For many families and clinicians, access to consistent, high-quality autism therapy remains a persistent challenge. If authorized, FloreoRx could become one of the first FDA-authorized therapeutic devices intended to address core social communication challenges associated with Autism Spectrum Disorder. Using a VR headset and FloreoRx, behavioral therapists deliver structured experiences that enable users to safely develop and practice social communication skills through real-world scenarios and interactions.

The submission is supported by data from Floreo’s pivotal trial which utilized FloreoRx within Applied Behavioral Analysis (ABA) autism therapy evaluated against an active VR sham control. The study was 100% monitored and among the largest prospective, multi-site randomized controlled trials of a VR-based intervention conducted in children with autism.

The pivotal trial was conducted in partnership with Cortica Healthcare (Cortica) across 18 clinical sites nationwide, leveraging Cortica’s gold-standard integrated autism care model. Additionally, MCRA served as CRO and Highland BioMed provided strategic regulatory assistance with the preparation of the De Novo submission.

The trial focused on core social communication challenges associated with Autism Spectrum Disorder, assessed using the Autism Impact Measure (AIM). At clinically interpretable thresholds of improvement, participants receiving Floreo treatment demonstrated higher responder rates than those in the VR control group (e.g., 45.6% vs. 23.3%), with statistically significant differences between groups. These results were supported by consistent improvements across clinician-rated and functional measures.

Importantly, this trial also reflects the scale and operational capacity required to generate meaningful results in real-world care settings. Cortica enrolled 125 patients and coordinated more than 150 behavioral technician VR coaches and 15 blinded assessors across all sites involved in the study over a 15-month period, spanning both blinded therapy delivery and crossover.

“The clinical research continues to validate what clinicians and families are seeing every day: immersive VR can meaningfully support skill development for autistic learners,” said Vijay Ravindran, founder and CEO of Floreo. “Three things stand out in the trial: 1) That Floreo could achieve statistically significant results with a dosage of 18 minutes per week over 12 weeks, 2) That Floreo performed better as the severity of symptoms increased, and 3) that improvements continued to strengthen after 60 days.”

Clinical Highlights Include:

Social Skills: Clinician-administered CARS-2 evaluations showed a statistically significant LSMean change of -4.5 for the Floreo group versus -2.2 for the control (p = .0182).Subgroup Analysis (Highest-Burden Baseline): Participants in the highest-burden tertile at baseline demonstrated a 72% responder rate compared to 30% in the control group (p=0.009).Post-Treatment Observation: Improvements observed in AIM scores for the FloreoRx group at the 12-week end-of-treatment mark were sustained at the 60-day follow-up evaluation.High Skill Mastery: A majority of participants (95.1%) mastered one or more new skills by the end of treatment, as measured by the Assessment of Functional Living Skills.Family Quality of Life: Caregiver-reported CFQL-2 reports on family quality of life showed a between groups difference that was statistically significant for the Floreo group versus the control of 0.152 (p = 0.032).Crossover Findings: Participants who initially received the VR control demonstrated improvements after transitioning to Floreo treatment, supporting the consistency of the observed treatment effect.Safety Profile: No serious adverse events were reported in the study, and observed adverse events were generally mild and transient.High Engagement and Satisfaction Across Stakeholders: High levels of satisfaction were reported across clinicians and caregivers, including clinician-reported enjoyment of VR (98%) and willingness to use it as a treatment tool (88%), as well as parent-reported child enjoyment (93%) and interest in using VR as part of therapy (86%).

If authorized, Floreo intends to make FloreoRx available as an adjunct to existing therapeutic approaches, with the goal of expanding access to structured, skills-based interventions for the approximately 3% of children in the United States diagnosed with Autism Spectrum Disorder, where access to consistent, high-quality therapy remains a significant challenge.

Floreo currently offers a commercially available VR platform designed for general wellness and skills development that does not make medical or therapeutic claims. FloreoRx is a separate investigational product under FDA review.

About Floreo
Floreo’s vision is a world that is open and accessible for every neurodiverse person. Through immersive virtual reality experiences, Floreo creates safe, engaging environments where learners can build skills and tools they can apply in their everyday lives. Floreo’s virtual reality platform teaches social, behavioral, communication, and life skills for individuals with Autism Spectrum Disorder and other neurodiverse conditions. For more information, please visit floreovr.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/following-pivotal-trial-fda-set-to-review-first-of-a-kind-vr-autism-therapy-302746375.html

SOURCE Floreo